Too Good to Be True.
Kirsten Jorgensen, John O Schorge
Author Information
- Kirsten Jorgensen: Dr. Jorgensen is from Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, Massachusetts. Dr. Schorge is Chief of Gynecologic Oncology at Tufts Medical Center, Boston, Massachusetts, and Associate Editor (Gynecology) for Obstetrics & Gynecology; email: jschorge@greenjournal.org.
No abstract text available.
- Lu KH, Cun HT. Unanswered questions in high-risk women undergoing risk-reducing salpingo-oophorectomy. Obstet Gynecol 2020;135:495–7.
- Hereditary breast and ovarian cancer syndrome. Practice Bulletin No. 182. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;130:e110–26.
- Doren A, Vecchiola A, Aguirre B, Villaseca P. Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations. Climacteric 2018;21:529–35.
- Nebgen DR, Hurteau J, Holman LL, Bradford A, Munsell MF, Soletsky BR, et al. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: a pilot study in women with BRCA1/2 mutations. Gynecol Oncol 2018;150:79–84.
- Leblanc E, Narducci F, Farre I, Peyrat JP, Taieb S, Adenis C, et al. Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development. Gynecol Oncol 2011;121:472–6.
- Harmsen MG, Arts-de Jong M, Hoogerbrugge N, Maas AH, Prins JB, Bulten J, et al. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers (TUBA study): a prospective non-randomised multicenter study. BMC Cancer 2015;15:593.
- Gaba F, Piek J, Menon U, Manchada R. Risk-reducing salpingectomy and delayed oophorectomy as two-staged alternative for primary prevention of ovarian cancer in women at increased risk: a commentary. BJOG 2019;126:831–9.
- Lugo Santiago N, Smith E, Cox M, Wan CS, Tchabo NE, Awowole A, et al. Ovarian cancer after prophylactic salpingectomy in a patient with germline BRCA1 mutation. Obstet Gynecol 2020;135:1270–4.
- Norquist BM, Garcia RL, Allison KH, Jokinen CH, Kernochan LE, Pizzi CC, et al. The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer 2010;116:5261–71.
BRCA1 Protein
Carcinoma, Ovarian Epithelial
Female
Germ Cells
Humans
Mutation
Ovarian Neoplasms
Salpingectomy
BRCA1 Protein
BRCA1 protein, human
